Allergen Submissions to the Allergen Nomenclature Database
Download Allergen Submission Form
(PDF, 595 KB)
- Investigators should download and complete the allergen submission form. This form should
contain as much relevant information about the proposed new allergen as possible and may be
accompanied by additional data (e.g. mass spectrometry, ELISA, Western blots, patient data).
Ideally, the form should be submitted as soon as data on the allergen have been completed
and prior to submitting the allergen for publication. The completed form should be submitted
by e-mail to: Dr. Christian Radauer (email@example.com).
- Please note the following requirements for submitted allergens candidates:
- IgE binding data must be obtained using sufficiently purified (natural or
recombinant) allergens. Identifying IgE binding bands or spots on 1D or 2D Western
blots will not be sufficient.
- The expression of the tested allergen in a tissue or organ that is relevant for human
exposure must be demonstrated at the mRNA and/or protein level. Proof of protein
expression is preferred and may also be provided by indirect methods, such as an
inhibition assay in which binding of human IgE or a specific antibody to an extract
is inhibited by the recombinant allergen. Detection of the mRNA should specifically
show the expression of the isoallergen that was used for IgE testing.
- Submissions must include the (at least partial) sequence of the allergen, which
must be accessible via a public sequence database such as NCBI or UniProt (access to
database entries may be blocked until publication).
- IgE binding must be tested using sera from a sufficiently high number of patients
allergic to the source of the allergen. Allergy must be diagnosed using common
clinical standards (at least based on typical symptoms combined with confirmation of
sensitization by skin test and/or specific IgE test).
- The proposed allergen should bind IgE from at least 5 of the tested sera. A lower
number can only be accepted for allergens from sources to which allergic reactions
are rare (e.g. occupational allergen sources) and for which it may be difficult to
obtain a sufficiently high number of patients.
- At least two members of the Sub-Committee will review the submission and assess
whether the allergen fulfills the molecular and immunological requirements for
inclusion into the allergen nomenclature database. The reviewers will also check for
homologies with other known allergens and for any ambiguities with named allergens.
The review process will take approximately four weeks after the date of submission.
The Sub-Committee may request additional information prior to deciding to grant (or
deny) an allergen name. In some cases, the Sub-Committee may suggest that the allergen
be renamed based on pre-existing data or homologies with previously named allergens.
- The chair of the Sub-Committee will notify investigators about the status of the
proposed new allergen. If the allergen is deemed to fulfill the requirements, the
investigators can use the new allergen name in publications, presentations, etc.
- Once the allergen name has been approved by the chair and the two primary reviewers,
information about the allergen will be included in the Allergen Nomenclature Database